B. 1. Endo and A. , A historical perspective on the discovery of statins, Proceedings of the Japan Academy, Series B, vol.86, issue.5, pp.484-93, 2010.
DOI : 10.2183/pjab.86.484

B. Sablonnière, Le métabolisme du cholestérol et des stéroïdes, Chimie, biochimie & biologie moléculaire : UE1 -Atomes, biomolécules, génome, bioénergétique, métabolisme, Omniscience, Editor, pp.474-482, 2010.

J. Weil, Biosynthèse du cholestérol, Biochimie générale, pp.312-316, 2001.

A. Avignon and P. Barbe, Athérosclérose: les hyperlipoprotéinémies. Cahiers de Nutrition et de Diététique, pp.2-101, 2001.

D. Steinberg, An interpretive history of the cholesterol controversy, part V: The discovery of the statins and the end of the controversy, Journal of Lipid Research, vol.347, issue.7, pp.47-1339, 2006.
DOI : 10.1016/j.clpt.2005.05.013

A. Endo, The discovery and development of HMG-CoA reductase inhibitors, Atherosclerosis Supplements, vol.5, issue.3, pp.67-80, 1992.
DOI : 10.1016/j.atherosclerosissup.2004.08.026

M. Schachter, Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update, Fundamental and Clinical Pharmacology, vol.14, issue.1, pp.117-142, 2005.
DOI : 10.1016/S0378-4274(03)90352-3

P. Duriez, M??canismes d???action des statines et des fibrates, Th??rapie, vol.58, issue.1, pp.5-14, 2003.
DOI : 10.2515/therapie:2003002

M. Andrejak, Adverse effects of statins. Thérapie, pp.77-83, 2003.

D. N. Kiortsis, Statin-associated adverse effects beyond muscle and liver toxicity, Afssaps, Risque musculaire des statines - Mise au point, pp.7-16, 2007.
DOI : 10.1016/j.atherosclerosis.2006.10.001

L. Becquemont, P. J. Neuvonen, M. Niemi, and J. T. Backman, Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance Afssaps, Prise en charge thérapeutique du patient dyslipidémique, Clin Pharmacol Ther, vol.58, issue.15, pp.85-90, 2003.

P. H. Jones, Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial, Clinical Therapeutics, vol.26, issue.9, pp.26-1388, 2004.
DOI : 10.1016/j.clinthera.2004.09.006

M. R. Law, N. J. Wald, and A. R. Rudnicka, Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis, 1423. 18. HAS, Efficacité et efficience des hypolipémiants : une analyse centrée sur les statines, 2003.
DOI : 10.1136/bmj.326.7404.1423

G. Luc, Hypolip??miants : bilan des grandes ??tudes cardiovasculaires, Th??rapie, vol.58, issue.1, pp.23-32, 2003.
DOI : 10.2515/therapie:2003004

T. R. Pedersen, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Atheroscler Suppl NICE, NICE implementation uptake report: statins for the prevention of cardiovascular events, pp.81-88, 1994.

S. Sakshaug, Lipid modifying drugs Statistics from the Norwegian Prescription Database Switching statins in Norway after new reimbursement policy: a nationwide prescription study, NIPH, Statistics from the Norwegian Prescription Database Davignon, J. and L. Mabile, Mécanismes d'action des statines et leurs effets pléiotropes. Annales d'endocrinologie, pp.476-81, 2001.

F. X. Ma and Z. C. Han, Statins, Nitric Oxide and Neovascularization, Cardiovascular Drug Reviews, vol.80, issue.18, pp.281-92, 2005.
DOI : 10.1161/01.RES.80.6.845

K. Wennerberg, K. L. Rossman, and C. J. Der, The Ras superfamily at a glance, Journal of Cell Science, vol.118, issue.5, pp.118-843, 2005.
DOI : 10.1242/jcs.01660

R. L. Sacco and J. K. Liao, Drug Insight: statins and stroke, Nature Clinical Practice Cardiovascular Medicine, vol.45, issue.Suppl, pp.576-84, 2005.
DOI : 10.1146/annurev.pharmtox.45.120403.095748

URL : http://europepmc.org/articles/pmc2743272?pdf=render

A. Sandoo, The Endothelium and Its Role in Regulating Vascular Tone, The Open Cardiovascular Medicine Journal, vol.4, issue.1, pp.302-314, 2010.
DOI : 10.2174/1874192401004010302

M. Pellegrin, Dysfonction endoth??liale et risque cardiovasculaire. L???exercice prot??ge la fonction endoth??liale et pr??vient la maladie cardiovasculaire, Science & Sports, vol.24, issue.2, pp.63-73, 2008.
DOI : 10.1016/j.scispo.2008.10.003

H. Ait-oufella, The endothelium: A new organ. Réanimation, pp.126-136, 2008.

T. Munzel, Vascular Consequences of Endothelial Nitric Oxide Synthase Uncoupling for the Activity and Expression of the Soluble Guanylyl Cyclase and the cGMP-Dependent Protein Kinase, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.25, issue.8, pp.25-1551, 2005.
DOI : 10.1161/01.ATV.0000168896.64927.bb

S. Dimmeler, Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation, Nature, vol.99, issue.6736, pp.399-601, 1999.
DOI : 10.1016/0076-6879(83)99075-4

V. A. Morrow, Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. The Journal of biological chemistry, pp.278-31629, 2003.

C. Michiels, Endothelial cell functions, Journal of Cellular Physiology, vol.416, issue.3, pp.430-473, 2003.
DOI : 10.1007/978-1-4899-0179-8_47

K. Komori and P. M. Vanhoutte, Endothelium-Derived Hyperpolarizing Factor, Journal of Vascular Research, vol.27, issue.2-5, pp.238-245, 1990.
DOI : 10.1159/000158815

P. Gelosa, The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation. Vasc Health Risk Manag, pp.567-77, 2007.

M. Feletou and P. M. Vanhoutte, Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture) American journal of physiology. Heart and circulatory physiology, pp.291-985, 2006.

L. Brocq and M. , Endothelial Dysfunction: From Molecular Mechanisms to Measurement, Clinical Implications, and Therapeutic Opportunities, Antioxidants & Redox Signaling, vol.10, issue.9, pp.1631-74, 2008.
DOI : 10.1089/ars.2007.2013

J. V. Mombouli and P. M. Vanhoutte, Endothelial Dysfunction: From Physiology to Therapy, Journal of Molecular and Cellular Cardiology, vol.31, issue.1, pp.31-61, 1999.
DOI : 10.1006/jmcc.1998.0844

J. Haendeler, Antioxidant Effects of Statins via S-Nitrosylation and Activation of Thioredoxin in Endothelial Cells: A Novel Vasculoprotective Function of Statins, Circulation, vol.110, issue.7, pp.110-856, 2004.
DOI : 10.1161/01.CIR.0000138743.09012.93

U. Laufs, Upregulation of Endothelial Nitric Oxide Synthase by HMG CoA Reductase Inhibitors, Circulation, vol.97, issue.12, pp.97-1129, 1998.
DOI : 10.1161/01.CIR.97.12.1129

O. Hernandez-perera, Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells., Journal of Clinical Investigation, vol.101, issue.12, pp.101-2711, 1998.
DOI : 10.1172/JCI1500

M. Landsberger, Blockade of geranylgeranylation by rosuvastatin upregulates eNOS expression in human venous endothelial cells. Biochemical and biophysical research communications, pp.1005-1014, 2005.

W. H. Kaesemeyer, Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions, Journal of the American College of Cardiology, vol.33, issue.1, pp.234-275, 1999.
DOI : 10.1016/S0735-1097(98)00514-2

Q. Zhou and J. K. Liao, Pleiotropic effects of statins. -Basic research and clinical perspectives, Circulation journal : official journal of the Japanese Circulation Society, issue.5, pp.74-818, 2010.

B. Tesfamariam, The Effects of HMG-CoA Reductase Inhibitors on Endothelial Function, American Journal of Cardiovascular Drugs, vol.15, issue.13
DOI : 10.1161/01.ATV.20.2.556

U. Laufs and J. K. Liao, Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. The Journal of biological chemistry, pp.273-24266, 1998.

Y. Rikitake and J. K. Liao, Rho GTPases, Statins, and Nitric Oxide, Circulation Research, vol.97, issue.12, pp.97-1232, 2005.
DOI : 10.1161/01.RES.0000196564.18314.23

URL : http://circres.ahajournals.org/content/circresaha/97/12/1232.full.pdf

M. Endres and U. Laufs, Effects of statins on endothelium and signaling mechanisms. Stroke; a journal of cerebral circulation, pp.2708-2719, 2004.

L. Yao, The role of RhoA/Rho kinase pathway in endothelial dysfunction, Journal of cardiovascular disease research, vol.1, issue.4, pp.165-70, 2010.

I. Kosmidou, Statin treatment and 3' polyadenylation of eNOS mRNA. Arteriosclerosis, thrombosis, and vascular biology, pp.27-2642, 2007.

Y. Kureishi, The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals., Nature Medicine, vol.33, issue.3 Pt 1, pp.1004-1014, 2000.
DOI : 10.1016/S0741-5214(00)81008-3

A. Skaletz-rorowski, HMG-CoA reductase inhibitors promote cholesterol-dependent Akt/PKB translocation to membrane domains in endothelial cells, Cardiovascular Research, vol.57, issue.1, pp.253-64, 2003.
DOI : 10.1016/S0008-6363(02)00618-1

J. Wang, Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-AKT pathway in endothelial cells, Life sciences, pp.76-2257, 2005.
DOI : 10.1016/j.lfs.2004.12.003

Y. Mukai, Acute Vasodilator Effects of HMG-CoA Reductase Inhibitors: Involvement of P13-kinase/Akt Pathway and Kv Channels, Journal of Cardiovascular Pharmacology, vol.42, issue.1, pp.118-142, 2003.
DOI : 10.1097/00005344-200307000-00018

M. B. Harris, Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors, American Journal of Physiology-Heart and Circulatory Physiology, vol.287, issue.2, pp.560-566, 2004.
DOI : 10.1016/S0165-6147(03)00163-9

C. Aoki, Fluvastatin upregulates endothelial nitric oxide synthase activity via enhancement of its phosphorylation and expression and via an increase in tetrahydrobiopterin in vascular endothelial cells, International Journal of Cardiology, vol.156, issue.1, 2010.
DOI : 10.1016/j.ijcard.2010.10.029

R. Merla, The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation, American Journal of Physiology-Heart and Circulatory Physiology, vol.293, issue.3, pp.1918-1946, 2007.
DOI : 10.1152/ajpheart.00210.2007

A. Brouet, Hsp90 and caveolin are key targets for the proangiogenic nitric oxidemediated effects of statins, Circ Res, issue.10, pp.89-866, 2001.

J. Martinez-gonzalez and L. Badimon, Influence of Statin Use on Endothelial Function: From Bench to Clinics, Current Pharmaceutical Design, vol.13, issue.17, pp.13-1771, 2007.
DOI : 10.2174/138161207780831220

W. Sun, Statins Activate AMP-Activated Protein Kinase In Vitro and In Vivo, Circulation, vol.114, issue.24, pp.2655-62, 2006.
DOI : 10.1161/CIRCULATIONAHA.106.630194

L. V. Rossoni, Acute simvastatin increases endothelial nitric oxide synthase phosphorylation via AMP-activated protein kinase and reduces contractility of isolated rat mesenteric resistance arteries, Clinical Science, vol.23, issue.10, pp.121-449, 1979.
DOI : 10.1016/j.cmet.2006.05.005

URL : https://hal.archives-ouvertes.fr/hal-00720574

R. Kou, J. Sartoretto, and T. Michel, Regulation of Rac1 by Simvastatin in Endothelial Cells, Journal of Biological Chemistry, vol.8, issue.22, pp.284-14734, 2009.
DOI : 10.1042/0264-6021:3620481

K. Noma, N. Oyama, and J. K. Liao, Physiological role of ROCKs in the cardiovascular system, American Journal of Physiology-Cell Physiology, vol.290, issue.3, pp.661-669, 2006.
DOI : 10.1161/01.RES.73.1.205

O. Feron, Hydroxy-Methylglutaryl-Coenzyme A Reductase Inhibition Promotes Endothelial Nitric Oxide Synthase Activation Through a Decrease in Caveolin Abundance, Circulation, vol.103, issue.1, pp.113-121, 2001.
DOI : 10.1161/01.CIR.103.1.113

M. Pelat, Rosuvastatin Decreases Caveolin-1 and Improves Nitric Oxide-Dependent Heart Rate and Blood Pressure Variability in Apolipoprotein E-/- Mice In Vivo, Circulation, vol.107, issue.19, pp.107-2480, 2003.
DOI : 10.1161/01.CIR.0000065601.83526.3E

K. Ozaki, Regulation of Endothelial Nitric Oxide Synthase and Endothelin-1 Expression by Fluvastatin in Human Vascular Endothelial Cells., The Japanese Journal of Pharmacology, vol.85, issue.2, pp.147-54, 2001.
DOI : 10.1254/jjp.85.147

M. Ohkita, Differential effects of different statins on endothelin-1 gene expression and endothelial NOS phosphorylation in porcine aortic endothelial cells, Experimental biology and medicine, issue.6, pp.231-772, 2006.

O. Hernandez-perera, Involvement of Rho GTPases in the Transcriptional Inhibition of Preproendothelin-1 Gene Expression by Simvastatin in Vascular Endothelial Cells, Circulation Research, vol.87, issue.7, pp.616-638, 2000.
DOI : 10.1161/01.RES.87.7.616

T. Ichiki, Downregulation of Angiotensin II Type 1 Receptor by Hydrophobic 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Vascular Smooth Muscle Cells, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.21, issue.12, pp.21-1896, 2001.
DOI : 10.1161/hq1201.099430

S. Wolfrum, K. S. Jensen, and J. K. Liao, Endothelium-dependent effects of statins. Arteriosclerosis, thrombosis, and vascular biology, pp.729-765, 2003.

A. G. Tristano, Effects of statin treatment and withdrawal on angiotensin II-induced phosphorylation of p38 MAPK and ERK1/2 in cultured vascular smooth muscle cells. Biochemical and biophysical research communications, pp.353-364, 2007.

H. Seeger, A. O. Mueck, and T. H. Lippert, Fluvastatin increases prostacyclin and decreases endothelin production by human umbilical vein endothelial cells, Int. Journal of Clinical Pharmacology and Therapeutics, vol.38, issue.05, pp.38-270, 2000.
DOI : 10.5414/CPP38270

C. Skogastierna, Beneficial vasoactive endothelial effects of fluvastatin: focus on prostacyclin and nitric oxide, Heart and Vessels, vol.1, issue.Suppl 2, pp.628-664, 2011.
DOI : 10.2174/1573404052950302

Q. Zhou, Y. Zhou, and F. A. Kummerow, High-dose lovastatin decreased basal prostacyclin production in cultured endothelial cells, Prostaglandins & Other Lipid Mediators, vol.89, issue.1-2, pp.1-7, 2009.
DOI : 10.1016/j.prostaglandins.2008.12.005

J. Martinez-gonzalez, I. Escudero, and L. Badimon, Simvastatin potenciates PGI(2) release induced by HDL in human VSMC: effect on Cox-2 up-regulation and MAPK signalling pathways activated by HDL, Atherosclerosis, issue.2, pp.174-305, 2004.

A. H. Wagner, Improvement of Nitric Oxide-Dependent Vasodilatation by HMG-CoA Reductase Inhibitors Through Attenuation of Endothelial Superoxide Anion Formation, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.20, issue.1, pp.61-70, 2000.
DOI : 10.1161/01.ATV.20.1.61

S. Wassmann, Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arteriosclerosis, thrombosis, and vascular biology, pp.300-305, 2002.

S. Wassmann, Inhibition of Geranylgeranylation Reduces Angiotensin II-Mediated Free Radical Production in Vascular Smooth Muscle Cells: Involvement of Angiotensin AT1 Receptor Expression and Rac1 GTPase, Molecular Pharmacology, vol.59, issue.3, pp.59-646, 2001.
DOI : 10.1124/mol.59.3.646

E. Alvarez, Pravastatin Counteracts Angiotensin II-Induced Upregulation and Activation of NADPH Oxidase at Plasma Membrane of Human Endothelial Cells, Journal of Cardiovascular Pharmacology, vol.55, issue.2, pp.203-215, 2010.
DOI : 10.1097/FJC.0b013e3181ce5f5a

L. L. Stoll, Antioxidant effects of statins. Timely topics in medicine. Cardiovascular diseases, p.1, 2005.

N. Grosser, The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells. Free radical biology & medicine, pp.37-2064, 2004.

F. Ali, Statin-mediated cytoprotection of human vascular endothelial cells: a role for Kruppel-like factor 2-dependent induction of heme oxygenase-1, Journal of Thrombosis and Haemostasis, vol.19, issue.12, pp.2537-2583, 2007.
DOI : 10.1161/01.ATV.20.1.61

S. Makabe, Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway, Atherosclerosis, vol.213, issue.2, pp.377-84, 2010.
DOI : 10.1016/j.atherosclerosis.2010.07.059

F. Ali, Induction of the Cytoprotective Enzyme Heme Oxygenase-1 by Statins Is Enhanced in Vascular Endothelium Exposed to Laminar Shear Stress and Impaired by Disturbed Flow, Journal of Biological Chemistry, vol.83, issue.28, pp.284-18882, 2009.
DOI : 10.1074/jbc.M313897200

U. Hinkelmann, Simvastatin-dependent up-regulation of heme oxygenase-1 via mRNA stabilization in human endothelial cells, European Journal of Pharmaceutical Sciences, vol.41, issue.1, pp.41-118, 2010.
DOI : 10.1016/j.ejps.2010.05.021

U. Laufs, Beyond lipid-lowering: effects of statins on endothelial nitric oxide, European Journal of Clinical Pharmacology, vol.104, issue.11, pp.58-719, 2003.
DOI : 10.1161/hc4601.099485

M. Terblanche, Statins and sepsis: multiple modifications at multiple levels, The Lancet Infectious Diseases, vol.7, issue.5, pp.358-68, 2007.
DOI : 10.1016/S1473-3099(07)70111-1

P. Carmeliet, Mechanisms of angiogenesis and arteriogenesis, Nature Medicine, vol.153, issue.4, pp.389-95, 2000.
DOI : 10.1016/S0002-9440(10)65654-4

J. D. Hood, VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. The American journal of physiology, pp.1054-1062, 1998.

I. Shiojima and K. Walsh, Role of Akt Signaling in Vascular Homeostasis and Angiogenesis, Circulation Research, vol.90, issue.12, pp.90-1243, 2002.
DOI : 10.1161/01.RES.0000022200.71892.9F

S. Dimmeler, HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway, Journal of Clinical Investigation, vol.108, issue.3, pp.391-398, 2001.
DOI : 10.1172/JCI200113152

J. Llevadot, HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells. The Journal of clinical investigation The effects of HMG-CoA reductase inhibitor on vascular progenitor cells, Journal of pharmacological sciences, vol.108, issue.1014, pp.399-405, 2001.

T. Nakao, Pravastatin Induces Rat Aortic Endothelial Cell Proliferation and Migration via Activation of PI3K/Akt/mTOR/p70 S6 Kinase Signaling, Journal of Pharmacological Sciences, vol.105, issue.4, pp.334-375, 2007.
DOI : 10.1254/jphs.FP0070682

J. Chen, Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke, Annals of Neurology, vol.275, issue.6, pp.743-51, 2003.
DOI : 10.1074/jbc.M006509200

H. J. Park, 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Interfere With Angiogenesis by Inhibiting the Geranylgeranylation of RhoA, Circulation Research, vol.91, issue.2, pp.91-143, 2002.
DOI : 10.1161/01.RES.0000028149.15986.4C

J. Dulak, Atorvastatin affects several angiogenic mediators in human endothelial cells. Endothelium : journal of endothelial cell research, pp.5-6, 2005.

L. Vincent, Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect, FEBS Letters, vol.86, issue.3, pp.495-159, 2001.
DOI : 10.1016/S0002-9149(00)00910-3

I. Sato, Simvastatin, a potent HMG-CoA Reductase Inhibitor, inhibits the Proliferation of Human and Bovine Endothelial Cells in vitro, Journal of Atherosclerosis and Thrombosis, vol.4, issue.3, pp.102-108, 1998.
DOI : 10.5551/jat1994.4.102

L. Vincent, Cerivastatin, an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase, Inhibits Endothelial Cell Proliferation Induced by Angiogenic Factors In Vitro and Angiogenesis in In Vivo Models, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.22, issue.4, pp.623-632, 2002.
DOI : 10.1161/01.ATV.0000012283.15789.67

M. Asakage, 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (pravastatin) inhibits endothelial cell proliferation dependent on G1 cell cycle arrest. Anti-cancer drugs, pp.15-625, 2004.

S. Miura, Y. Matsuo, and K. Saku, Simvastatin suppresses coronary artery endothelial tube formation by disrupting Ras/Raf/ERK signaling, Atherosclerosis, vol.175, issue.2, pp.235-278, 2004.
DOI : 10.1016/j.atherosclerosis.2004.04.017

P. Negre-aminou, Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types, Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, vol.1345, issue.3, pp.1345-259, 1997.
DOI : 10.1016/S0005-2760(96)00184-1

M. Frick, Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells, Atherosclerosis, vol.170, issue.2, pp.229-265, 2003.
DOI : 10.1016/S0021-9150(03)00299-5

J. Chen, Atorvastatin Induction of VEGF and BDNF Promotes Brain Plasticity after Stroke in Mice, Journal of Cerebral Blood Flow & Metabolism, vol.269, issue.2, pp.25-281, 2005.
DOI : 10.1161/hh0302.104460

A. Nishimoto-hazuku, Simvastatin stimulates vascular endothelial growth factor production by hypoxia-inducible factor-1alpha upregulation in endothelial cells, Journal of cardiovascular pharmacology, issue.3, pp.51-267, 2008.

X. Li and B. Xu, HMG-CoA reductase inhibitor regulates endothelial progenitor function through the phosphatidylinositol 3'-kinase/AKT signal transduction pathway. Applied biochemistry and biotechnology, pp.545-53, 2009.

M. Weis, Statins Have Biphasic Effects on Angiogenesis, Circulation, vol.105, issue.6, pp.739-784, 2002.
DOI : 10.1161/hc0602.103393

C. Urbich, Double-Edged Role of Statins in Angiogenesis Signaling, Circulation Research, vol.90, issue.6, pp.90-737, 2002.
DOI : 10.1161/01.RES.0000014081.30867.F8

M. Katsumoto, Biphasic Effect of HMG-CoA Reductase Inhibitor, Pitavastatin, on Vascular Endothelial Cells and Angiogenesis, Circulation Journal, vol.69, issue.12, pp.69-1547, 2005.
DOI : 10.1253/circj.69.1547

Y. Izumi, Pravastatin accelerates ischemia-induced angiogenesis through AMPactivated protein kinase Hypertension research : official journal of the, pp.32-675, 2009.

X. Li, AMP-activated protein kinase promotes the differentiation of endothelial progenitor cells. Arteriosclerosis, thrombosis, and vascular biology, Diverse effects of statins on angiogenesis: new therapeutic avenues. Pharmacotherapy, pp.1789-95, 2008.

L. Vincent, Insights in the molecular mechanisms of the anti-angiogenic effect of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, Thrombosis and haemostasis, issue.3, pp.89-530, 2003.

M. Massaro, Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability, Cardiovascular Research, vol.90, issue.2, pp.311-331, 2010.
DOI : 10.1016/S0167-5273(02)00577-6

A. Skaletz-rorowski and K. Walsh, Statin therapy and angiogenesis, Current Opinion in Lipidology, vol.14, issue.6, pp.599-603, 2003.
DOI : 10.1097/00041433-200312000-00008

X. Y. Zhu, Disparate effects of simvastatin on angiogenesis during hypoxia and inflammation, Life Sciences, vol.83, issue.23-24, pp.23-24, 2008.
DOI : 10.1016/j.lfs.2008.09.029

M. Ii and D. W. Losordo, Statins and the endothelium, Vascular Pharmacology, vol.46, issue.1, pp.1-9, 2007.
DOI : 10.1016/j.vph.2006.06.012

A. Undas, K. E. Brummel-ziedins, and K. G. Mann, Statins and blood coagulation. Arteriosclerosis, thrombosis, and vascular biology, pp.287-94, 2005.
DOI : 10.1161/01.atv.0000151647.14923.ec

URL : http://atvb.ahajournals.org/content/atvbaha/25/2/287.full.pdf

R. Krysiak, B. Okopien, Z. Herman, T. , and K. Doghmi, Effects of HMG-CoA Reductase Inhibitors on Coagulation and Fibrinolysis Processes, Haemostasis, blood platelets and coagulation. Anaesthesia & Intensive Care Medicine, pp.63-1821, 2003.
DOI : 10.2165/00003495-200363170-00005

M. Levi, H. Cate, T. Van-der-poll, and V. W. , Endothelium: interface between coagulation and inflammation The endothelium: vascular control of haemostasis, Crit Care Med Eur J Obstet Gynecol Reprod Biol, vol.30, issue.52, pp.95-198, 2001.

V. W. Van-hinsbergh, Endothelium???role in regulation of coagulation and inflammation, Seminars in Immunopathology, vol.5, issue.19, 2011.
DOI : 10.1038/15271

J. K. Liao and U. Laufs, Pleiotropic effects of statins. Annual review of pharmacology and toxicology, pp.89-118, 2005.

J. K. Liao, Effects of Statins on 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition Beyond Low-Density Lipoprotein Cholesterol, The American Journal of Cardiology, vol.96, issue.5, pp.96-120, 2005.
DOI : 10.1016/j.amjcard.2005.06.009

U. Laufs, Atorvastatin Upregulates Type III Nitric Oxide Synthase in Thrombocytes, Decreases Platelet Activation, and Protects From Cerebral Ischemia in Normocholesterolemic Mice Editorial Comment, Stroke, vol.31, issue.10, pp.31-2442, 2000.
DOI : 10.1161/01.STR.31.10.2442

T. C. Chou, Enhanced nitric oxide and cyclic GMP formation plays a role in the anti-platelet activity of simvastatin, British Journal of Pharmacology, vol.44, issue.6, pp.1281-1288, 2008.
DOI : 10.1007/978-1-4615-2994-1_20

G. R. Wang, Mechanism of platelet inhibition by nitric oxide: In vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase, Proceedings of the National Academy of Sciences, vol.43, issue.2, pp.95-4888, 1998.
DOI : 10.1016/S0092-8674(00)80117-8

E. Butt, cAMP-and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets, J Biol Chem, issue.20, pp.269-14509, 1994.

M. Alvarez-de-sotomayor and R. Andriantsitohaina, Simvastatin and Ca2+ Signaling in Endothelial Cells: Involvement of Rho Protein, Biochemical and Biophysical Research Communications, vol.280, issue.2, pp.486-90, 2001.
DOI : 10.1006/bbrc.2000.4144

K. H. Le-quan-sang, Platelet cytosolic Ca2+ and membrane dynamics in patients with primary hypercholesterolemia. Effects of pravastatin, Arterioscler Thromb Vasc Biol, issue.6, pp.15-759, 1995.

R. J. Fish, Fluvastatin inhibits regulated secretion of endothelial cell von Willebrand factor in response to diverse secretagogues, Biochemical Journal, vol.405, issue.3, pp.405-597, 2007.
DOI : 10.1042/BJ20070404

F. Y. Ali, Role of nuclear receptor signaling in platelets: antithrombotic effects of PPAR??, The FASEB Journal, vol.20, issue.2, pp.326-334, 2006.
DOI : 10.1096/fj.05-4395fje

F. Y. Ali, Antiplatelet Actions of Statins and Fibrates Are Mediated by PPARs, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.29, issue.5, pp.29-706, 2009.
DOI : 10.1161/ATVBAHA.108.183160

S. Colli, Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arteriosclerosis, thrombosis, and vascular biology, pp.265-72, 1997.

A. Hilgendorff, Statins differ in their ability to block NF-kappaB activation in human blood monocytes, International journal of clinical pharmacology and therapeutics, issue.9, pp.41-397, 2003.

D. Ferro, Inhibition of tissue-factor-mediated thrombin generation by simvastatin, Atherosclerosis, vol.149, issue.1, pp.111-117, 2000.
DOI : 10.1016/S0021-9150(99)00291-9

M. Cortellaro, Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study, Thromb Haemost, vol.88, issue.1, pp.41-48, 2002.

K. Goralczyk, The influence of lovastatin on thrombomodulin gene expression in vascular endothelial cells--in vitro study., Folia Histochemica et Cytobiologica, vol.47, issue.1, pp.43-48, 2009.
DOI : 10.2478/v10042-009-0012-4

S. Morikawa, Global Analysis of RNA Expression Profile in Human Vascular Cells Treated with Statins, Journal of Atherosclerosis and Thrombosis, vol.11, issue.2, pp.62-72, 2004.
DOI : 10.5551/jat.11.62

K. Masamura, Pitavastatin-Induced Thrombomodulin Expression by Endothelial Cells Acts Via Inhibition of Small G Proteins of the Rho Family, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.23, issue.3, pp.512-519, 2003.
DOI : 10.1161/01.ATV.0000060461.64771.F0

J. Shi, Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation, Blood Coagulation & Fibrinolysis, vol.14, issue.6, pp.14-575, 2003.
DOI : 10.1097/00001721-200309000-00010

S. J. Lin, Pravastatin induces thrombomodulin expression in TNF??-treated human aortic endothelial cells by inhibiting Rac1 and Cdc42 translocation and activity, Journal of Cellular Biochemistry, vol.8, issue.3, pp.642-53, 2007.
DOI : 10.5551/jat.9.178

E. M. Conway, Heat shock of vascular endothelial cells induces an up-regulatory transcriptional response of the thrombomodulin gene that is delayed in onset and does not attenuate, The Journal of biological chemistry, issue.36, pp.269-22804, 1994.

Q. Fu, Involvement of Heat Shock Factor 1 in Statin-Induced Transcriptional Upregulation of Endothelial Thrombomodulin, Circulation Research, vol.103, issue.4, pp.369-77, 2008.
DOI : 10.1161/CIRCRESAHA.108.174607

M. Essig, 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Increase Fibrinolytic Activity in Rat Aortic Endothelial Cells : Role of Geranylgeranylation and Rho Proteins, Circulation Research, vol.83, issue.7, pp.83-683, 1998.
DOI : 10.1161/01.RES.83.7.683

F. Wiesbauer, HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins, British Journal of Pharmacology, vol.17, issue.1, pp.284-92, 2002.
DOI : 10.1161/01.ATV.17.3.465

T. Bourcier and P. Libby, HMG CoA Reductase Inhibitors Reduce Plasminogen Activator Inhibitor-1 Expression by Human Vascular Smooth Muscle and Endothelial Cells, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.20, issue.2, pp.556-62, 2000.
DOI : 10.1161/01.ATV.20.2.556

J. W. Fenton, Statin drugs and dietary isoprenoids downregulate protein prenylation in signal transduction and are antithrombotic and prothrombolytic agents, Biochemistry (Moscow), vol.67, issue.1, pp.85-91, 2002.
DOI : 10.1023/A:1013956215394

P. Quist-paulsen, Statins and inflammation: an update. Current opinion in cardiology, pp.399-405, 2010.
DOI : 10.1097/hco.0b013e3283398e53

P. M. Ridker, Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men, New England Journal of Medicine, vol.336, issue.14, pp.336-973, 1997.
DOI : 10.1056/NEJM199704033361401

P. M. Ridker, C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women, New England Journal of Medicine, vol.342, issue.12, pp.342-836, 2000.
DOI : 10.1056/NEJM200003233421202

M. A. Albert, Effect of Statin Therapy on C-Reactive Protein Levels, JAMA, vol.286, issue.1, pp.64-70, 2001.
DOI : 10.1001/jama.286.1.64

O. Grip, S. Janciauskiene, and S. Lindgren, Pravastatin down-regulates inflammatory mediators in human monocytes in vitro, European Journal of Pharmacology, vol.410, issue.1, pp.83-92, 2000.
DOI : 10.1016/S0014-2999(00)00870-0

J. L. Paul, Physiopathologie de l???ath??roscl??rose et marqueurs pr??coces, Revue Francophone des Laboratoires, vol.2009, issue.409, pp.41-50, 2009.
DOI : 10.1016/S1773-035X(09)70199-6

P. Libby, Inflammatory mechanisms: the molecular basis of inflammation and disease, Nutr Rev, vol.12, issue.2, pp.65-140, 2007.

M. K. Jain and P. M. Ridker, Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms, Nature Reviews Drug Discovery, vol.40, issue.12, pp.977-87, 2005.
DOI : 10.1097/00005344-200211000-00013

J. Rossi, Laminar shear stress prevents simvastatin-induced adhesion molecule expression in cytokine activated endothelial cells, European Journal of Pharmacology, vol.649, issue.1-3, pp.1-3, 2010.
DOI : 10.1016/j.ejphar.2010.09.016

K. A. Eccles, Simvastatin alters human endothelial cell adhesion molecule expression and inhibits leukocyte adhesion under flow, Atherosclerosis, vol.200, issue.1, pp.69-79, 2008.
DOI : 10.1016/j.atherosclerosis.2007.12.018

A. Schmidt, Lovastatin-stimulated superinduction of E-selectin, ICAM-1 and VCAM-1 in TNF-?? activated human vascular endothelial cells, Atherosclerosis, vol.164, issue.1, pp.57-64, 2002.
DOI : 10.1016/S0021-9150(02)00053-9

T. C. Izidoro-toledo, Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells, Naunyn-Schmiedeberg's Archives of Pharmacology, vol.19, issue.7, pp.383-547, 2011.
DOI : 10.1161/01.ATV.19.7.1700

L. M. Blanco-colio, Anti-inflammatory and immunomodulatory effects of statins, Kidney International, vol.63, issue.1, pp.12-23, 2003.
DOI : 10.1046/j.1523-1755.2003.00744.x

S. Morikawa, The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells, J Atheroscler Thromb, issue.94, pp.178-83, 2002.

I. Inoue, Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect, Life Sciences, vol.67, issue.8, pp.67-863, 2000.
DOI : 10.1016/S0024-3205(00)00680-9

Y. Wang, The effect of atorvastatin on mRNA levels of inflammatory genes expression in human peripheral blood lymphocytes by DNA microarray, Biomedicine & Pharmacotherapy, vol.65, issue.2, pp.65-118, 2011.
DOI : 10.1016/j.biopha.2010.12.005

U. Schonbeck and P. Libby, Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents?, Circulation, vol.109, issue.21_suppl_1, pp.18-26, 2004.
DOI : 10.1161/01.CIR.0000129505.34151.23

URL : http://circ.ahajournals.org/content/circulationaha/109/21_suppl_1/II-18.full.pdf

A. H. Wagner, 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells. Arteriosclerosis, thrombosis, and vascular biology, pp.22-1784, 2002.

F. Mulhaupt, Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovascular research, pp.755-66, 2003.

H. Chen, Direct Effects of Statins on Cells Primarily Involved in Atherosclerosis., Hypertension Research, vol.23, issue.2, pp.187-92, 2000.
DOI : 10.1291/hypres.23.187

L. M. Biasucci, G. Biasillo, and A. Stefanelli, Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance. Clinical chemistry and laboratory medicine : CCLM / FESCC, pp.48-1685, 2010.
DOI : 10.1515/cclm.2010.277

M. Yoshida, HMG-CoA Reductase Inhibitor Modulates Monocyte-Endothelial Cell Interaction Under Physiological Flow Conditions In Vitro : Involvement of Rho GTPase-Dependent Mechanism, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.21, issue.7, pp.1165-71, 2001.
DOI : 10.1161/hq0701.092143

N. R. Veillard, Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages, Atherosclerosis, vol.188, issue.1, pp.51-59, 2006.
DOI : 10.1016/j.atherosclerosis.2005.10.015

B. M. Maher, Statins alter neutrophil migration by modulating cellular Rho activity--a potential mechanism for statins-mediated pleotropic effects?, Journal of Leukocyte Biology, vol.85, issue.1, pp.186-93, 2009.
DOI : 10.1189/jlb.0608382

W. Dichtl, HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arteriosclerosis, thrombosis, and vascular biology, pp.58-63, 2003.

K. Brand, Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion., Journal of Clinical Investigation, vol.97, issue.7, pp.97-1715, 1996.
DOI : 10.1172/JCI118598

M. Ortego, Atorvastatin reduces NF-??B activation and chemokine expression in vascular smooth muscle cells and mononuclear cells, Atherosclerosis, vol.147, issue.2, pp.253-61, 1999.
DOI : 10.1016/S0021-9150(99)00193-8

R. Lin, Lovastatin Reduces Nuclear Factor κB Activation Induced by C-Reactive Protein in Human Vascular Endothelial Cells, Biological and Pharmaceutical Bulletin, vol.28, issue.9, pp.1630-1634, 2005.
DOI : 10.1248/bpb.28.1630

T. T. Tuomisto, Simvastatin has an anti-inflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2, Cardiovascular Research, vol.107, issue.1, pp.78-175, 2008.
DOI : 10.1182/blood-2005-08-3465

S. Senbanerjee, KLF2 Is a Novel Transcriptional Regulator of Endothelial Proinflammatory Activation, The Journal of Experimental Medicine, vol.275, issue.10, pp.199-1305, 2004.
DOI : 10.1016/S0092-8674(00)81118-6

K. M. Parmar, Statins exert endothelial atheroprotective effects via the KLF2 transcription factor. The Journal of biological chemistry, pp.280-26714, 2005.

S. Sen-banerjee, Kruppel-Like Factor 2 as a Novel Mediator of Statin Effects in Endothelial Cells, Circulation, vol.112, issue.5, pp.720-726, 2005.
DOI : 10.1161/CIRCULATIONAHA.104.525774

A. Pucci, PPAR?? in coronary atherosclerosis: In vivo expression pattern and correlations with hyperlipidemic status and statin treatment, Atherosclerosis, vol.218, issue.2, pp.479-85, 2011.
DOI : 10.1016/j.atherosclerosis.2011.06.009

N. Marx, Peroxisome Proliferator-Activated Receptors and Atherogenesis: Regulators of Gene Expression in Vascular Cells, Circulation Research, vol.94, issue.9, pp.94-1168, 2004.
DOI : 10.1161/01.RES.0000127122.22685.0A

R. Paumelle, Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway, Circ Res, issue.3, pp.98-361, 2006.

O. Grip, S. Janciauskiene, and S. Lindgren, Atorvastatin activates PPAR-?? and attenuates the inflammatory response in human monocytes, Inflammation Research, vol.93, issue.2, pp.58-62, 2002.
DOI : 10.4049/jimmunol.164.2.1046

J. Greenwood and J. C. Mason, Statins and the vascular endothelial inflammatory response, Trends in Immunology, vol.28, issue.2, pp.88-98, 2007.
DOI : 10.1016/j.it.2006.12.003

S. John, Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients, American Heart Journal, vol.149, issue.3, pp.473-436, 2005.
DOI : 10.1016/j.ahj.2004.06.027

M. Glorian, Revue francophone des laboratoires, p.389, 2007.

S. H. Wilson, Simvastatin Preserves Coronary Endothelial Function in Hypercholesterolemia in the Absence of Lipid Lowering, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.21, issue.1, pp.122-130, 2001.
DOI : 10.1161/01.ATV.21.1.122

J. R. Murrow, The differential effect of statins on oxidative stress and endothelial function: Atorvastatin versus pravastatin, Journal of Clinical Lipidology, vol.6, issue.1, pp.42-51, 2012.
DOI : 10.1016/j.jacl.2011.08.006

J. Rodes-cabau, Acute Effects of Statin Therapy on Coronary Atherosclerosis Following an Acute Coronary Syndrome, The American Journal of Cardiology, vol.104, issue.6, pp.750-757, 2009.
DOI : 10.1016/j.amjcard.2009.05.009

M. Crisby, Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques : Implications for Plaque Stabilization, Circulation, vol.103, issue.7, pp.926-959, 2001.
DOI : 10.1161/01.CIR.103.7.926

H. Kunte, Markers of instability in high-risk carotid plaques are reduced by statins, Journal of Vascular Surgery, vol.47, issue.3, pp.47-513, 2008.
DOI : 10.1016/j.jvs.2007.11.045

M. Koutouzis, Statin treated patients have reduced intraplaque angiogenesis in carotid endarterectomy specimens, Atherosclerosis, vol.192, issue.2, pp.457-63, 2007.
DOI : 10.1016/j.atherosclerosis.2007.01.035

S. E. Nissen, Effect of Intensive Lipid Lowering on Progression of Coronary Atherosclerosis: Evidence for an Early Benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Trial, The American Journal of Cardiology, vol.96, issue.5, pp.96-61, 2005.
DOI : 10.1016/j.amjcard.2005.07.013

S. E. Nissen, Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis, JAMA, vol.295, issue.13, pp.295-1556, 2006.
DOI : 10.1001/jama.295.13.jpc60002

S. J. Nicholls, Effect of two intensive statin regimens on progression of coronary disease, N Engl J Med, issue.22, pp.365-2078, 2011.

U. Bedi, Effects of Statins on Progression of Coronary Artery Disease as Measured by Intravascular Ultrasound, The Journal of Clinical Hypertension, vol.92, issue.7, pp.13-492, 2011.
DOI : 10.1161/01.CIR.92.7.1758

T. Walter, Effect of Atorvastatin on Haemostasis, Fibrinolysis and Inflammation in Normocholesterolaemic Patients with Coronary Artery Disease, Clinical Drug Investigation, vol.96, issue.5A, pp.30-453, 2010.
DOI : 10.1111/j.1365-2362.2007.01891.x

M. A. Ostad, Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: Results of the CEZAR study, Atherosclerosis, vol.205, issue.1, pp.227-259, 2009.
DOI : 10.1016/j.atherosclerosis.2008.11.032

J. Bonnet, Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: Results of the CAP (Comparative Atorvastatin Pleiotropic effects) study, Clinical Therapeutics, vol.30, issue.12, pp.30-2298, 2008.
DOI : 10.1016/j.clinthera.2008.12.023

J. Lablanche, Statin therapy in acute coronary syndromes. Thérapie, pp.59-62, 2003.

N. Danchin, Epidemiology of acute coronary syndromes in France and in Europe, 2010. 59 Suppl, pp.37-41

F. Angeli, Very early initiation of statin therapy and mortality in patients with acute coronary syndrome, Acute Cardiac Care, vol.103, issue.1, pp.34-43, 2012.
DOI : 10.1080/10623320303359

G. G. Schwartz, Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial, Jama, issue.13, pp.285-1711, 2001.

C. P. Cannon, Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes, New England Journal of Medicine, vol.350, issue.15, pp.350-1495, 2004.
DOI : 10.1056/NEJMoa040583

K. K. Ray, Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes, Journal of the American College of Cardiology, vol.46, issue.8, pp.46-1405, 2005.
DOI : 10.1016/j.jacc.2005.03.077

M. Briel, Updated evidence on early statin therapy for acute coronary syndromes: Meta-analysis of 18 randomized trials involving over 14,000 patients, International Journal of Cardiology, vol.158, issue.1, pp.93-100, 2011.
DOI : 10.1016/j.ijcard.2011.01.033

A. A. Bavry, Long-Term Benefit of Statin Therapy Initiated??during Hospitalization for??an??Acute??Coronary Syndrome, American Journal of Cardiovascular Drugs, vol.48, issue.2, pp.135-176, 2007.
DOI : 10.2165/00129784-200707020-00005

E. Hulten, The Effect of Early, Intensive Statin Therapy on Acute Coronary Syndrome, Archives of Internal Medicine, vol.166, issue.17, pp.166-1814, 2006.
DOI : 10.1001/archinte.166.17.1814

M. C. Kim, Early statin therapy within 48 hours decreased one-year major adverse cardiac events in patients with acute myocardial infarction European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts), Int Heart J Atherosclerosis, vol.52, issue.2231, pp.1-68, 2011.

R. Blumenthal and R. Redberg, Should healthy people take cholesterol drugs to prevent heart disease?, Wall Street Journal, 2012.

P. H. Joshi, A Point-by-Point Response to Recent Arguments Against the Use of Statins in Primary Prevention, Clinical Cardiology, vol.378, issue.7, pp.35-404, 2012.
DOI : 10.1016/S0140-6736(11)60784-8

C. M. Minder, Evidence-based Use of Statins for Primary Prevention of Cardiovascular Disease, The American Journal of Medicine, vol.125, issue.5, pp.440-446, 2012.
DOI : 10.1016/j.amjmed.2011.11.013

J. J. Brugts, The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials, BMJ, vol.338, issue.jun30 1, p.2376, 2009.
DOI : 10.1136/bmj.b2376

K. K. Ray, Statins and All-Cause Mortality in High-Risk Primary Prevention, Archives of Internal Medicine, vol.170, issue.12, pp.170-1024, 2010.
DOI : 10.1001/archinternmed.2010.182

F. Taylor, K. Ward, and T. Moore, Statins for the primary prevention of cardiovascular disease, Cochrane Database Syst Rev, 2011.

S. Kaul, R. P. Morrissey, and G. A. Diamond, By Jove! What Is a Clinician to Make of JUPITER?, Archives of Internal Medicine, vol.170, issue.12, pp.1073-1080, 2010.
DOI : 10.1001/archinternmed.2010.189

P. M. Ridker, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, pp.359-2195, 2008.

M. De-lorgeril, Cholesterol Lowering, Cardiovascular Diseases, and the Rosuvastatin-JUPITER Controversy, Archives of Internal Medicine, vol.170, issue.12, pp.1032-1038, 2010.
DOI : 10.1001/archinternmed.2010.184

URL : https://hal.archives-ouvertes.fr/hal-00849312

S. Ward, A systematic review and economic evaluation of statins for the prevention of coronary events, Health Technology Assessment, vol.11, issue.14, pp.1-160, 2007.
DOI : 10.3310/hta11140

M. R. Clergeau, Int??r??t des statines dans la pr??vention des infarctus postangioplastie coronaire??: revue syst??matique et m??ta-analyse, Annales de Cardiologie et d'Ang??iologie, vol.57, issue.3, pp.181-187, 2008.
DOI : 10.1016/j.ancard.2008.02.001

V. Pasceri, Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation, pp.110-674, 2004.

J. Luo, Effect of Statins Therapy Prior to Percutaneous Coronary Intervention, Journal of Interventional Cardiology, vol.110, issue.9, pp.156-62, 2012.
DOI : 10.1161/01.CIR.0000140261.58966.A4

G. Patti, Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention, Journal of the American College of Cardiology, vol.49, issue.12, pp.49-1272, 2007.
DOI : 10.1016/j.jacc.2007.02.025

D. Sciascio and G. , Efficacy of Atorvastatin Reload in Patients on Chronic Statin Therapy Undergoing Percutaneous Coronary Intervention, Journal of the American College of Cardiology, vol.54, issue.6, pp.54-558, 2009.
DOI : 10.1016/j.jacc.2009.05.028

C. Briguori, Novel Approaches for Preventing or Limiting Events (Naples) II Trial, Journal of the American College of Cardiology, vol.54, issue.23, pp.54-2157, 2009.
DOI : 10.1016/j.jacc.2009.07.005

G. Sardella, Rosuvastatin pre-treatment in patients undergoing elective PCI to reduce the incidence of myocardial periprocedural necrosis. The ROMA trial, Catheter Cardiovasc Interv, 2012.

S. Post, Early statin treatment prior to primary PCI for acute myocardial infarction: REPERATOR, a randomized placebo-controlled pilot trial, Catheterization and Cardiovascular Interventions, vol.40, issue.5, 2012.
DOI : 10.1016/S0735-1097(02)02115-0

J. Y. Hahn, Effects of atorvastatin pretreatment on infarct size in patients with STsegment elevation myocardial infarction undergoing primary percutaneous coronary intervention, Am Heart J, issue.6, pp.162-1026, 2011.

J. A. Lardizabal and P. C. Deedwania, The anti-ischemic and anti-anginal properties of statins. Current atherosclerosis reports, pp.43-50, 2011.

M. Sénard, Statins in the perioperative period : Take it or leave it? Le Praticien en anesthésie réanimation, pp.344-350, 2009.

B. Hibbert, Pre-Procedural Atorvastatin Mobilizes Endothelial Progenitor Cells: Clues to the Salutary Effects of Statins on Healing of Stented Human Arteries, PLoS ONE, vol.360, issue.1, p.16413, 2011.
DOI : 10.1371/journal.pone.0016413.t002

E. W. Kuhn, Current evidence for perioperative statins in cardiac surgery. The Annals of thoracic surgery, pp.372-381, 2011.

A. Kulik and M. Ruel, Statins and coronary artery bypass graft surgery: preoperative and postoperative efficacy and safety, Expert Opinion on Drug Safety, vol.17, issue.5, pp.559-71, 2009.
DOI : 10.1001/archinte.162.4.468

J. T. Christenson, Preoperative lipid-control with simvastatin reduces the risk of postoperative thrombocytosis and thrombotic complications following CABG1, European Journal of Cardio-Thoracic Surgery, vol.19, issue.Suppl., pp.394-403, 1999.
DOI : 10.1001/jama.279.20.1643

J. T. Christenson, Preoperative lipid control with simvastatin protects coronary artery bypass grafts from obstructive graft disease, The American Journal of Cardiology, vol.88, issue.8, pp.896-905, 2001.
DOI : 10.1016/S0002-9149(01)01901-4

V. A. Mannacio, Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: A randomized trial, The Journal of Thoracic and Cardiovascular Surgery, vol.136, issue.6, pp.1541-1549, 2008.
DOI : 10.1016/j.jtcvs.2008.06.038

O. J. Liakopoulos, Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30,000 patients, European heart journal, issue.12, pp.29-1548, 2008.

P. M. Haydock, Heart failure: classification and pathophysiology, Medicine, vol.38, issue.9, pp.467-472, 2010.
DOI : 10.1016/j.mpmed.2010.06.006

H. Kouadja, Insuffisance cardiaque aiguë aux urgences

D. Pouchain, Prise en charge du patient insuffisant cardiaque chronique. La revue Exercer, pp.1-4, 2003.

K. K. Khush, Effect of High-Dose Atorvastatin on Hospitalizations for Heart Failure: Subgroup Analysis of the Treating to New Targets (TNT) Study, Circulation, vol.115, issue.5, pp.115-576, 2007.
DOI : 10.1161/CIRCULATIONAHA.106.625574

A. Hognestad, Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure, The American Journal of Cardiology, vol.93, issue.5, pp.93-603, 2004.
DOI : 10.1016/j.amjcard.2003.11.027

C. E. Angermann and S. Nitschmann, Statin therapy for systolic heart failure. The CORONA trial (Controlled Rosuvastatin Multinational Trial in Heart Failure), Internist (Berl), issue.7, pp.49-884, 2008.

L. Tavazzi, Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial, Lancet, issue.9645, pp.372-1231, 2008.

M. J. Lipinski, Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure. The American journal of cardiology, pp.1708-1724, 2009.

K. Ramasubbu, Experimental and Clinical Basis for the Use of Statins in Patients With Ischemic and Nonischemic Cardiomyopathy, Journal of the American College of Cardiology, vol.51, issue.4, pp.415-441, 2008.
DOI : 10.1016/j.jacc.2007.10.009

U. Laufs, F. Custodis, and M. Bohm, HMG-CoA Reductase Inhibitors in Chronic Heart Failure, Drugs, vol.6, issue.5, pp.145-54, 2006.
DOI : 10.1016/j.ejheart.2004.03.001

S. Sola, Statin Therapy Is Associated With Improved Cardiovascular Outcomes and Levels of Inflammatory Markers in Patients With Heart Failure, Journal of Cardiac Failure, vol.11, issue.8, pp.11-607, 2005.
DOI : 10.1016/j.cardfail.2005.05.011

U. Landmesser, Simvastatin Versus Ezetimibe: Pleiotropic and Lipid-Lowering Effects on Endothelial Function in Humans, Circulation, vol.111, issue.18, pp.2356-63, 2005.
DOI : 10.1161/01.CIR.0000164260.82417.3F

S. Erbs, High-dose rosuvastatin in chronic heart failure promotes vasculogenesis, corrects endothelial function, and improves cardiac remodeling ??? Results from a randomized, double-blind, and placebo-controlled study, International Journal of Cardiology, vol.146, issue.1, pp.146-56, 2011.
DOI : 10.1016/j.ijcard.2010.02.019

X. L. Tang, Atorvastatin Therapy during the Peri-Infarct Period Attenuates Left Ventricular Dysfunction and Remodeling after Myocardial Infarction, PLoS ONE, vol.152, issue.9, p.25320, 2011.
DOI : 10.1371/journal.pone.0025320.g007

S. Sola, Atorvastatin Improves Left Ventricular Systolic Function and Serum Markers of Inflammation in Nonischemic Heart Failure, Journal of the American College of Cardiology, vol.47, issue.2, pp.47-332, 2006.
DOI : 10.1016/j.jacc.2005.06.088

M. J. Lipinski, Drug Insight: statins for nonischemic heart failure???evidence and potential mechanisms, Nature Clinical Practice Cardiovascular Medicine, vol.6, issue.4, pp.196-205, 2007.
DOI : 10.1016/j.ejheart.2004.03.001

B. Moosmann and C. Behl, Selenoprotein synthesis and side-effects of statins Fédération française de cardiologie, Activité électrique du coeur Cardiac Action Group, Ventricular tachycardia, Lancet, vol.275, issue.9412, pp.363-892, 2004.

A. Beri, Statins and the Reduction of Sudden Cardiac Death, American Journal Cardiovascular Drugs, vol.5, issue.4, pp.155-64, 2010.
DOI : 10.1161/01.CIR.103.13.1813

M. S. Kostapanos, Do statins have an antiarrhythmic activity? Cardiovasc Res, pp.10-20, 2007.

A. K. Vyas, Reduction in Ventricular Tachyarrhythmias With Statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II, Journal of the American College of Cardiology, vol.47, issue.4, pp.47-769, 2006.
DOI : 10.1016/j.jacc.2005.09.053

J. J. Goldberger, Effects of Statin Therapy on Arrhythmic Events and Survival in Patients With Nonischemic Dilated Cardiomyopathy, Journal of the American College of Cardiology, vol.48, issue.6, pp.48-1228, 2006.
DOI : 10.1016/j.jacc.2006.05.053

M. G. Dickinson, Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: Mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), American Heart Journal, vol.153, issue.4
DOI : 10.1016/j.ahj.2007.02.002

C. I. Coleman, Association between statin use and mortality in patients with implantable cardioverter-defibrillators and left ventricular systolic dysfunction, Heart Rhythm, vol.5, issue.4, pp.507-517, 2008.
DOI : 10.1016/j.hrthm.2007.12.023

G. Levantesi, Meta-Analysis of Effect of Statin Treatment on Risk of Sudden Death, The American Journal of Cardiology, vol.100, issue.11, pp.100-1644, 2007.
DOI : 10.1016/j.amjcard.2007.07.015

B. Vrtovec, Atorvastatin Therapy May Reduce the Incidence of Sudden Cardiac Death in Patients With Advanced Chronic Heart Failure, Journal of Cardiac Failure, vol.14, issue.2, pp.140-144, 2008.
DOI : 10.1016/j.cardfail.2007.10.013

J. Kjekshus, Rosuvastatin in Older Patients with Systolic Heart Failure, New England Journal of Medicine, vol.357, issue.22, pp.357-2248, 2007.
DOI : 10.1056/NEJMoa0706201

K. Rahimi, Effect of statins on ventricular tachyarrhythmia, cardiac arrest, and sudden cardiac death: a meta-analysis of published and unpublished evidence from randomized trials, European Heart Journal, vol.6, issue.8, 2012.
DOI : 10.1177/1740774509105223

N. Wanahita, The Effect of Statin Therapy on Ventricular Tachyarrhythmias: A Meta-Analysis, American Journal of Therapeutics, vol.19, issue.1, pp.16-23, 2012.
DOI : 10.1097/MJT.0b013e3181e9087a

D. Sutter and J. , Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients, Journal of the American College of Cardiology, vol.36, issue.3, pp.766-72, 2000.
DOI : 10.1016/S0735-1097(00)00787-7

S. Riahi, Statins, Ventricular Arrhythmias and Heart Rate Variability in Patients with Implantable Cardioverter Defibrillators and Coronary Heart Disease, Cardiology, vol.350, issue.4, pp.210-214, 2005.
DOI : 10.1161/01.CIR.93.5.1043

L. B. Mitchell, Are lipid-lowering drugs also antiarrhythmic drugs?, Journal of the American College of Cardiology, vol.42, issue.1, pp.81-88, 2003.
DOI : 10.1016/S0735-1097(03)00498-4

URL : https://doi.org/10.1016/s0735-1097(03)00498-4

D. Sutter and J. , CLARIDI Trial - Clinical Trial Results. www.clinicaltrialresults.org/Slides/CLARIDI

A. Vedre, Impact of Prior Statin Therapy on Arrhythmic Events in Patients With Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events [GRACE]), The American Journal of Cardiology, vol.104, issue.12, pp.104-1613, 2009.
DOI : 10.1016/j.amjcard.2009.07.045

G. C. Fonarow, Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality, Am J Cardiol, issue.5, pp.96-611, 2005.

M. I. Dotani, Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting, The American Journal of Cardiology, vol.86, issue.10, pp.1128-1158, 2000.
DOI : 10.1016/S0002-9149(00)01172-3

M. Kayikcioglu, The effect of statin therapy on ventricular late potentials in acute myocardial infarction, International Journal of Cardiology, vol.90, issue.1, pp.63-72, 2003.
DOI : 10.1016/S0167-5273(02)00516-8

X. Z. He, Retracted: The Effect of Early and Intensive Statin Therapy on Ventricular Premature Beat or Nonsustained Ventricular Tachycardia in Patients With Acute Coronary Syndrome, Clinical Cardiology, vol.144, issue.1, pp.59-63, 2010.
DOI : 10.1038/sj.bjp.0706020

L. C. Thuc, Cardioprotective Effects of Pravastatin Against Lethal Ventricular Arrhythmias Induced by Reperfusion in the Rat Heart, Circulation Journal, vol.75, issue.7, pp.75-1601, 2011.
DOI : 10.1253/circj.CJ-10-1139

J. Chen, Pravastatin Inhibits Arrhythmias Induced by Coronary Artery Ischemia in Anesthetized Rats, Journal of Pharmacological Sciences, vol.103, issue.3, pp.317-339, 2007.
DOI : 10.1254/jphs.FP0061235

H. L. Lazar, Pretreatment with statins enhances myocardial protection during coronary revascularization, The Journal of Thoracic and Cardiovascular Surgery, vol.125, issue.5, pp.1037-1079, 2003.
DOI : 10.1067/mtc.2003.177

URL : https://doi.org/10.1067/mtc.2003.177

D. Costa and A. , Fibrillation atriale : enjeux ??pid??miologiques, d??finition, nosologie, m??dico-??conomie, Annales de Cardiologie et d'Ang??iologie, vol.58, issue.1, pp.3-5, 2009.
DOI : 10.1016/S0003-3928(09)73388-8

Y. L. Lee, M. J. Blaha, and S. R. Jones, Statin therapy in the prevention and treatment of atrial fibrillation, Journal of Clinical Lipidology, vol.5, issue.1, pp.18-29, 2011.
DOI : 10.1016/j.jacl.2010.11.002

J. Dernellis and M. Panaretou, Effect of C-reactive protein reduction on paroxysmal atrial fibrillation, American Heart Journal, vol.150, issue.5, p.1064, 2005.
DOI : 10.1016/j.ahj.2005.06.032

Y. Hirayama, Long-Term Effects of Upstream Therapy on Paroxysmal Atrial Fibrillation in Patients Without Overt Heart Diseases, International Heart Journal, vol.50, issue.2, pp.141-51, 2009.
DOI : 10.1536/ihj.50.141

E. Watanabe, Statin Treatment for Patients With Paroxysmal Atrial Fibrillation, International Heart Journal, vol.52, issue.2, pp.103-109, 2011.
DOI : 10.1536/ihj.52.103

J. M. Pena, High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial, European Heart Journal, vol.42, issue.5, pp.531-538, 2012.
DOI : 10.1016/j.yjmcc.2007.03.807

C. T. Tsai, Atorvastatin prevents atrial fibrillation in patients with bradyarrhythmias and implantation of an atrial-based or dual-chamber pacemaker: A prospective randomized trial, American Heart Journal, vol.156, issue.1, pp.65-70, 2008.
DOI : 10.1016/j.ahj.2008.01.028

P. Santangeli, Usefulness of statins in preventing atrial fibrillation in patients with permanent pacemaker: a systematic review, Europace, vol.315, issue.7109, pp.649-54, 2010.
DOI : 10.1136/bmj.315.7109.629

T. Komatsu, Long-term Efficacy of Upstream Therapy With Lipophilic or Hydrophilic Statins on Antiarrhythmic Drugs in Patients With Paroxysmal Atrial Fibrillation, International Heart Journal, vol.52, issue.6, pp.52-359, 2011.
DOI : 10.1536/ihj.52.359

Y. Young-xu, Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. The American journal of cardiology, pp.92-1379, 2003.

C. N. Pellegrini, Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial, Heart, vol.95, issue.9, pp.95-704, 2009.
DOI : 10.1136/hrt.2008.154054

A. S. Adabag, D. B. Nelson, and H. E. Bloomfield, Effects of statin therapy on preventing atrial fibrillation in coronary disease and heart failure, American Heart Journal, vol.154, issue.6, pp.154-1140, 2007.
DOI : 10.1016/j.ahj.2007.07.018

A. Kulik, Association between statin use and the incidence of atrial fibrillation following hospitalization for coronary artery disease. The American journal of cardiology, pp.105-1655, 2010.

N. Danchin, Impact of early statin therapy on development of atrial fibrillation at the acute stage of myocardial infarction: data from the FAST-MI register, Heart, vol.96, issue.22, pp.96-1809, 2010.
DOI : 10.1136/hrt.2010.201574

G. G. Schwartz, Effect of intensive statin treatment on the occurrence of atrial fibrillation after acute coronary syndrome: an analysis of the MIRACL trial, Circulation, pp.110-740, 2004.

D. S. Mclean, Effect of statin dose on incidence of atrial fibrillation: Data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy???Thrombolysis in Myocardial Infarction 22 (PROVE IT???TIMI 22) and Aggrastat to Zocor (A to Z) trials, American Heart Journal, vol.155, issue.2, pp.155-298, 2008.
DOI : 10.1016/j.ahj.2007.10.024

L. Fauchier, Antiarrhythmic effect of statin therapy and atrial fibrillation a metaanalysis of randomized controlled trials, Journal of the American College of Cardiology, issue.8, pp.51-828, 2008.

M. G. Dickinson, AB24-2, Heart Rhythm, vol.3, issue.5, p.49, 2006.
DOI : 10.1016/j.hrthm.2006.02.161

I. R. Hanna, Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction, Heart Rhythm, vol.3, issue.8, pp.881-887, 2006.
DOI : 10.1016/j.hrthm.2006.05.010

A. P. Maggioni, Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial, European Heart Journal, vol.118, issue.12, pp.30-2327, 2009.
DOI : 10.1161/CIRCULATIONAHA.107.760892

I. Savelieva, Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, pp.13-308, 2011.

N. Girerd, Statins Reduce Short- and Long-Term Mortality Associated With Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting: Impact of Postoperative Atrial Fibrillation and Statin Therapy on Survival, Clinical Cardiology, vol.46, issue.7, pp.35-430, 2012.
DOI : 10.1016/j.jacc.2005.05.086

K. Lertsburapa, Preoperative statins for the prevention of atrial fibrillation after cardiothoracic surgery, The Journal of Thoracic and Cardiovascular Surgery, vol.135, issue.2, pp.405-416, 2008.
DOI : 10.1016/j.jtcvs.2007.08.049

G. Patti, Randomized Trial of Atorvastatin for Reduction of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery: Results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) Study, Circulation, vol.114, issue.14, pp.114-1455, 2006.
DOI : 10.1161/CIRCULATIONAHA.106.621763

A. Kourliouros, Dose-Related Effect of Statins on Atrial Fibrillation After Cardiac Surgery, The Annals of Thoracic Surgery, vol.85, issue.5, pp.1515-1535, 2008.
DOI : 10.1016/j.athoracsur.2008.01.040

S. Mithani, Dose dependent effect of statins on postoperative atrial fibrillation after cardiac surgery among patients treated with beta blockers, Journal of Cardiothoracic Surgery, vol.154, issue.1, pp.61-326, 2009.
DOI : 10.1016/j.ahj.2007.07.018

W. T. Chen, Effect of statins on atrial fibrillation after cardiac surgery: a duration-and dose-response meta-analysis. The Journal of thoracic and cardiovascular surgery, pp.140-364, 2010.

K. Subramaniam, Preoperative statin intake and morbid events after isolated coronary artery bypass grafting, Journal of Clinical Anesthesia, vol.20, issue.1, 2008.
DOI : 10.1016/j.jclinane.2007.09.003

S. S. Virani, Preoperative statin therapy is not associated with a decrease in the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery, American Heart Journal, vol.155, issue.3, pp.541-547, 2008.
DOI : 10.1016/j.ahj.2007.10.027

A. Miceli, Effects of Preoperative Statin Treatment on the Incidence of Postoperative Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Grafting, The Annals of Thoracic Surgery, vol.87, issue.6, pp.1853-1861, 2009.
DOI : 10.1016/j.athoracsur.2009.03.041

O. J. Liakopoulos, Statins for prevention of atrial fibrillation after cardiac surgery: a systematic literature review. The Journal of thoracic and cardiovascular surgery, pp.678-686, 2009.

V. Chopra, Effect of Perioperative Statins on Death, Myocardial Infarction, Atrial Fibrillation, and Length of Stay, Archives of Surgery, vol.147, issue.2, pp.181-190, 2012.
DOI : 10.1001/archsurg.2011.897

P. D. Bhave, Statin use and postoperative atrial fibrillation after major noncardiac surgery, Heart Rhythm, vol.2012, issue.92, pp.163-172
DOI : 10.1016/j.hrthm.2012.03.045

URL : http://europepmc.org/articles/pmc3439804?pdf=render

I. Savelieva, Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, pp.13-610, 2011.

A. Tveit, Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion, The American Journal of Cardiology, vol.93, issue.6, pp.93-780, 2004.
DOI : 10.1016/j.amjcard.2003.12.009

H. Almroth, Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study, European Heart Journal, vol.92, issue.11, pp.30-827, 2009.
DOI : 10.1016/j.amjcard.2003.08.023

S. Negi, Statin Therapy for the Prevention of Atrial Fibrillation Trial (SToP AF trial), Journal of Cardiovascular Electrophysiology, vol.29, issue.4, pp.414-423, 2011.
DOI : 10.1093/eurheartj/ehn011

A. Bhardwaj, Lack of effect of statins on maintenance of normal sinus rhythm following electrical cardioversion of persistent atrial fibrillation, International Journal of Clinical Practice, vol.50, issue.Suppl. 1, pp.64-1116, 2010.
DOI : 10.1161/01.CIR.96.10.3542

F. Dentali, Use of statins and recurrence of atrial fibrillation after catheter ablation or electrical cardioversion, Thrombosis and Haemostasis, vol.106, issue.2, pp.363-70, 2011.
DOI : 10.1160/TH10-10-0660

T. Liu, Statin use and development of atrial fibrillation: A systematic review and meta-analysis of randomized clinical trials and observational studies, International Journal of Cardiology, vol.126, issue.2, pp.160-70, 2008.
DOI : 10.1016/j.ijcard.2007.07.137

K. Rahimi, Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials, BMJ, vol.342, issue.mar16 2, p.1250, 2011.
DOI : 10.1136/bmj.d1250

K. Kumagai, H. Nakashima, and K. Saku, The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model, Cardiovascular Research, vol.62, issue.1, pp.105-116, 2004.
DOI : 10.1016/j.cardiores.2004.01.018

O. Adam, Role of Rac1 GTPase Activation in Atrial Fibrillation, Journal of the American College of Cardiology, vol.50, issue.4, pp.359-67, 2007.
DOI : 10.1016/j.jacc.2007.03.041

C. Maack, Oxygen Free Radical Release in Human Failing Myocardium Is Associated With Increased Activity of Rac1-GTPase and Represents a Target for Statin Treatment, Circulation, vol.108, issue.13, pp.1567-74, 2003.
DOI : 10.1161/01.CIR.0000091084.46500.BB

J. C. Reil, Cardiac Rac1 overexpression in mice creates a substrate for atrial arrhythmias characterized by structural remodelling, Cardiovascular Research, vol.110, issue.3, pp.485-93, 2010.
DOI : 10.1161/01.CIR.0000145163.56529.D1

F. Marin, Statins and Postoperative Risk of Atrial Fibrillation Following Coronary Artery Bypass Grafting, The American Journal of Cardiology, vol.97, issue.1, pp.55-60, 2006.
DOI : 10.1016/j.amjcard.2005.07.124

D. N. Tziakas, Effect of Statins on Collagen Type I Degradation in Patients With Coronary Artery Disease and Atrial Fibrillation, The American Journal of Cardiology, vol.101, issue.2, pp.199-202, 2008.
DOI : 10.1016/j.amjcard.2007.07.063